ProShare Advisors LLC increased its position in shares of ResMed Inc. (NYSE:RMD – Free Report) by 15.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,894 shares of the medical equipment provider’s stock after acquiring an additional 3,062 shares during the quarter. ProShare Advisors LLC’s holdings in ResMed were worth $5,014,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also recently modified their holdings of the company. Kayne Anderson Rudnick Investment Management LLC purchased a new stake in ResMed in the third quarter valued at $26,000. Compass Wealth Management LLC purchased a new position in ResMed during the fourth quarter worth about $26,000. International Assets Investment Management LLC increased its position in shares of ResMed by 3,940.0% during the first quarter. International Assets Investment Management LLC now owns 202 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 197 shares during the last quarter. Live Oak Investment Partners purchased a new stake in shares of ResMed in the 4th quarter valued at approximately $44,000. Finally, Ronald Blue Trust Inc. lifted its holdings in shares of ResMed by 34.6% in the 1st quarter. Ronald Blue Trust Inc. now owns 214 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 55 shares during the last quarter. Hedge funds and other institutional investors own 63.79% of the company’s stock.
Insider Buying and Selling
In related news, CEO Michael J. Farrell sold 5,675 shares of ResMed stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $221.27, for a total transaction of $1,255,707.25. Following the completion of the sale, the chief executive officer now owns 436,930 shares in the company, valued at approximately $96,679,501.10. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Michael J. Farrell sold 5,675 shares of the company’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $221.27, for a total transaction of $1,255,707.25. Following the completion of the transaction, the chief executive officer now owns 436,930 shares of the company’s stock, valued at approximately $96,679,501.10. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Kaushik Ghoshal sold 500 shares of the company’s stock in a transaction on Thursday, July 13th. The stock was sold at an average price of $220.00, for a total value of $110,000.00. Following the sale, the insider now owns 11,787 shares of the company’s stock, valued at $2,593,140. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,900 shares of company stock valued at $3,021,246. 1.39% of the stock is owned by insiders.
Wall Street Analyst Weigh In
ResMed Stock Performance
Shares of ResMed stock opened at $146.01 on Tuesday. The firm has a market capitalization of $21.47 billion, a P/E ratio of 23.94, a P/E/G ratio of 2.27 and a beta of 0.52. The company has a quick ratio of 1.81, a current ratio of 3.12 and a debt-to-equity ratio of 0.35. ResMed Inc. has a 52 week low of $145.00 and a 52 week high of $243.52. The firm’s 50 day moving average is $183.72 and its two-hundred day moving average is $207.16.
ResMed (NYSE:RMD – Get Free Report) last announced its earnings results on Thursday, August 3rd. The medical equipment provider reported $1.60 EPS for the quarter, missing analysts’ consensus estimates of $1.67 by ($0.07). The business had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.14 billion. ResMed had a net margin of 21.25% and a return on equity of 24.94%. The business’s revenue was up 22.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.49 earnings per share. Research analysts forecast that ResMed Inc. will post 7.08 EPS for the current fiscal year.
ResMed Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 21st. Shareholders of record on Thursday, August 17th will be issued a $0.48 dividend. The ex-dividend date is Wednesday, August 16th. This is a boost from ResMed’s previous quarterly dividend of $0.44. This represents a $1.92 dividend on an annualized basis and a yield of 1.31%. ResMed’s dividend payout ratio (DPR) is 31.48%.
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
- Five stocks we like better than ResMed
- How to Invest in the Best Canadian Stocks
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- How to Choose Top Rated Stocks
- 5 Reasons Mullen Automotive is About to Turn a Corner
- How and Why to Invest in Oil Stocks
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.